Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>Citi Lowers GIANT BIOGENE's TP to HKD44.6 w/ Rating Kept Buy
Recommend 1 Positive 3 Negative 1 |
||||
|
||||
|
GIANT BIOGENE (02367.HK)'s latest results guidance is at the lower end of market expectations, Citi wrote in its research report. Given the continued growth of its live-streaming business and the launch of several major new products, Citi expects GIANT BIOGENE to return to double-digit growth next year. Meanwhile, the company's management still anticipates revenue reaching RMB10 billion within 3-5 years. Citi kept a Buy rating on GIANT BIOGENE but cut its target price from HKD55.4 to HKD44.6. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
